Modified release suspension of eslicarbazepine
US11331324B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Mar 24, 2020 |
| Grant date | May 17, 2022 |
| Priority date | — |
| Expiry date | May 30, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/5047
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention discloses an extended release oral liquid pharmaceutical composition comprising eslicarbazepine or its pharmaceutically acceptable esters, salts, solvates, polymorphs, enantiomers or mixtures thereof in a pharmaceutically acceptable carrier. The extended release liquid compositions are in the form of ready-to-use liquid compositions or reconstituted liquid compositions. It also relates to processes for the preparation of said extended release liquid compositions. The prior art discloses immediate release oral liquid dosage form. The prepared novel test formulations exhibited desired pharmaceutical technical attributes.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.